Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy

Journal of Urology

Volumn 173, Issue 3, 2005, Pages 777-780

  Shen, Samson ^a   Lepor, Herbert ^a   Yaffee, Robert ^a   Taneja, Samir S ^a,b  

^a NEW YORK UNIVERSITY   (United States)

^b NY Univ Academic Computing Services ^*  (United States)

Author keywords

Prostate; Prostate specific antigen; Prostatectomy; Prostatic neoplasms; Recurrence

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADJUVANT THERAPY; ADULT; CHEMICAL ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; FOLLOW UP; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECURRENT DISEASE; RISK FACTOR; SALVAGE THERAPY;

EID: 13744255556     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000153619.33446.60     Document Type: Conference Paper

References (12)

1. Walsh, P. C. and Mostwin, J. L.: Radical prostatectomy and cystoprostatectomy with preservation of potency. Results using a new nerve-sparing technique. Br J Urol, 56: 694, 1984
2. Partin, A. W., Pound, C. R., Clemens, J. Q., Epstein, J. I. and Walsh, P. C.: Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am, 20: 713, 1993
3. Zincke, H., Oesterling, J. E., Blute, M. L., Bergstralh, E. J., Myers, R. P. and Barrett, D. M.: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol, 152: 1850, 1994
4. D'Amico, A. V., Whittington, R., Malkovicz, S. B., Fondurulia, J., Chen, M.-H., Tomaszewski, J. E. et al: The combination of preoperative prostate specific antigen and postoperative pathological findings to predict prostate specific antigen outcome in clinically localized prostate cancer. J Urol, 160: 2096, 1998
5. Lange, P. H., Ercole, C. J., Lightner, D. J., Fraley, E. E. and Vessella, R.: The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol, 141: 873, 1989
6. Schild, S. E., Buskirk, S. J., Wong, W. W., Halyard, M. Y., Swanson, S. K., Novicki, D. E. et al: The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. J Urol, 156: 1725, 1996
7. Ellis, W. J., Vessella, R. L., Noteboom, J. L., Lange, P. H., Wolfert, R. L. and Rittenhouse, H. G.: Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay. Urology, 50: 573, 1997
8. Vassilikos, E. J., Yu, H., Trachtenberg, J., Nam, R. K., Narod, S. A., Bromberg, I. L. et al: Relapse and cure rates of prostate cancer men after radical prostatectomy and 5 years of follow-up. Clin Biochem, 33: 115, 2000
9. Polascik, T. J., Oesterling, J. E. and Partin, A. W.: Prostate specific antigen: a decade of discovery - what we have learned and where we are going. J Urol, 162: 293, 1999
10. Partin, A. W., Kattan, M. W., Subong, E. N., Walsh, P. C., Wojno, K. J., Oesterling, J. E. et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA, 277: 1445, 1997
11. Han, M., Partin, A. W., Zahurak, M., Piantadosi, S., Epstein, J. I. and Walsh, P. C.: Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol, 169: 517, 2003
12. Doherty, A. P., Bower, M., Smith, G. L., Miano, R., Mannion, E. M., Mitchell, H. et al: Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival. Br J Cancer, 83: 1432, 2000